Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial)

American Journal of Cardiology

Volumn 93, Issue 9, 2004, Pages 1092-1096

  Lincoff, A Michael ^a   Bittl, John A ^b   Kleiman, Neal S ^b   Sarembock, Ian J ^b   Jackman, J Daniel ^b   Mehta, Sameer ^b   Tannenbaum, Mark A ^b   Niederman, Alan L ^b   Bachinsky, William B ^b   Tift Mann III, J ^b   Parker, H Graham ^b   Kereiakes, Dean J ^b   Harrington, Robert A ^b   Feit, Frederick ^b   Maierson, Elizabeth S ^b   Chew, Derek P ^b   Topol, Eric J ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; TIROFIBAN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING TIME; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTRAOCULAR HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROPERITONEAL HEMORRHAGE; RISK REDUCTION; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ANTITHROMBINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPARIN; HIRUDINS; HUMANS; INTRAOPERATIVE CARE; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PILOT PROJECTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS; TREATMENT OUTCOME; UNITED STATES; WHOLE BLOOD COAGULATION TIME;

EID: 11144357395     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.01.033     Document Type: Article

References (11)

1. Bittl J.A., Chaitman B.R., Feit F., Kimball W., Topol E.J., Bivalirudin Angioplasty Study Investigators. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 142:2001;952-959.
2. Lincoff A.M., Kleiman N.S., Kottke-Marchant K., Maierson E.S., Maresh K., Wolski K.E., Topol E.J. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J. 143:2002;847-853.
3. Lincoff A.M., Bittl J.A., Harrington R.A., Feit F., Kleiman N.S., Jackman J.D., Sarembock I.J., Cohen D.J., Spriggs D., Ebrahimi R., et al. REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. The REPLACE-2 trial. JAMA. 289:2003;853-863.
4. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronaryt stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet. 352:1998;87-92.
5. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT) a randomised, placebo-controlled trial. Lancet. 356:2000;2037-2044.
6. Topol E.J., Moliterno D.J., Herrmann H.C., Powers E.R., Grines C.L., Cohen D.J., Cohen E.A., Betrand M., Neumann F.J., Stone G.W., DiBattiste P.M., Demopoulos L., TARGET Investigators. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 344:2001;1888-1894.
7. Bittl J.A., Strony J., Brinker J.A., Ahmen W.H., Meckel C.R., Chaitman B.R., Maraganore J., Deutsch E., Adelman B., Hirulog Angioplasty Study Investigators. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med. 333:1995;764-769.
8. Lefkovits J., Topol E.J. Direct thrombin inhibitors in cardiovascular medicine. Circulation. 90:1994;1522-1536.
9. Weitz J.I., Hudoba M., Massel D., Maraganore J., Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III independent inhibitors. J Clin Invest. 86:1990;385-391.
10. Weitz J.I., Bates S.M. Acute coronary syndromes a focus on thrombin. J Invasive Cardiol. 14(suppl B):2002;2B-7B.
11. Kereiakes D.J., Lincoff A.M., Anderson K.M., Achenbach R., Patel K., Barnathan E., Califf R.M., Topol E.J., EPIC E, and EPISTENT Investigators. Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile. Am J Cardiol. 90:2002;628-630.